Model-Based Approach to Improve Clinical Outcomes in Neonates With Opioid Withdrawal Syndrome Using Real-World Data
JournalClinical Pharmacology and Therapeutics
MetadataShow full item record
AbstractAt least 60% of the neonates with opioid withdrawal syndrome (NOWS) require morphine to control withdrawal symptoms. Currently, the morphine dosing strategies are empiric, not optimal and associated with longer hospital stay. The aim of the study was to develop a quantitative, model-based, real-world data-driven approach to morphine dosing to improve clinical outcomes, such as reducing time on treatment. Longitudinal morphine dose, clinical response (Modified Finnegan Score (MFS)), and baseline risk factors were collected using a retrospective cohort design from the electronic medical records of neonates with NOWS (N = 177) admitted to the University of Maryland Medical Center. A dynamic linear mixed effects model was developed to describe the relationship between MFS and morphine dose adjusting for baseline risk factors using a split-sample data approach (70% training: 30% test). The training model was evaluated in the test dataset using a simulation based approach. Maternal methadone and benzodiazepine use, and race were significant predictors of the MFS response. Positive autocorrelations of 0.56 and 0.12 were estimated between consecutive MFS responses. On an average, for a 1,000 ?g increase in the morphine dose, the MFS decreased by 0.3 units. The model evaluation showed that observed and predicted median time on treatment were similar (13.0 vs. 13.8 days). A model-based framework was developed to describe the MFS -morphine dose relationship using real-world data that could potentially be used to develop an adaptive, individualized morphine dosing strategy to improve clinical outcomes in infants with NOWS. Copyright 2020 The Authors. Clinical Pharmacology & Therapeutics Copyright 2020 American Society for Clinical Pharmacology and Therapeutics
SponsorsThis study was funded by a Science to Systems Grant (SSG) Program from the University of Maryland, Baltimore - Center for Addiction Research, Education and Service (UMB CARES).
Neonatal Abstinence Syndrome--drug therapy
Opioid-Related Disorders--drug therapy
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15348
- Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.
- Authors: Merhar SL, Ounpraseuth S, Devlin LA, Poindexter BB, Young LW, Berkey SD, Crowley M, Czynski AJ, Kiefer AS, Whalen BL, Das A, Fuller JF, Higgins RD, Thombre V, Lester BM, Smith PB, Newman S, Sánchez PJ, Smith MC, Simon AE, EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT NEONATAL RESEARCH NETWORK AND THE NIH ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES (ECHO) PROGRAM INSTITUTIONAL DEVELOPMENT AWARDS STATES PEDIATRIC CLINICAL TRIALS NETWORK.
- Issue date: 2021 Mar
- Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
- Authors: Davis JM, Shenberger J, Terrin N, Breeze JL, Hudak M, Wachman EM, Marro P, Oliveira EL, Harvey-Wilkes K, Czynski A, Engelhardt B, D'Apolito K, Bogen D, Lester B
- Issue date: 2018 Aug 1
- A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations.
- Authors: Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI
- Issue date: 2005 Oct
- Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.
- Authors: Young ME, Hager SJ, Spurlock D Jr
- Issue date: 2015 Dec 1
- [Drug withdrawal in newborns - clinical data of 49 infants with intrauterine drug exposure: what should be done?].
- Authors: Bläser A, Pulzer F, Knüpfer M, Robel-Tillig E, Vogtmann C, Nickel P, Kiess W
- Issue date: 2008 Sep-Oct